Back to search

Peptide record

TPDB42919

9[Orn] [Pal] Anticancer modified_plain modified
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42919
9[Orn] [Pal]
Anticancer
Cancer-related peptides
CancerPPD 2.0
modified_plain
Yes
A 9-aa modified anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation Chemical: O=Ornithine
Sequence
RWQWRWQWO-NH2
Physicochemical Analysis
C66H82N20O11
ANDCEGHILKMFPSTYV
W
1331.50
12.40
2
0
4
+2
-4.62
-2.178
0.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
22000
1652.27
2
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
2
Q
0
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
0
S
0
T
4
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 2 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 0 T: 0 W: 4 Y: 0 V: 0
Chemical Descriptors
9
C66H82N20O11
1331.50
12.40
+2
-4.62
-2.178
Amidation
O=Ornithine
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 109 µM
Anticancer
109 µM

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 40 µM
Anticancer
40 µM

Target

Colorectal Cancer
CaCo-2
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

IC50
IC50 = 62 µM
Anticancer
62 µM

Target

Prostrate Cancer
DU-145
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023